United States

Galapagos NV (GLPG.AS1)

GLPG.AS1 on Amsterdam Stock Exchange

16 Jan 2017
Change (% chg)

€-0.64 (-0.98%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067
Wednesday, 22 Mar 2017 02:31am EDT 

Galapagos NV : Initiates Phase 1 study with novel CF potentiator GLPG3067 . Triggers a $7.5 million milestone payment from AbbVie . Third potentiator in growing portfolio of cystic fibrosis drug candidates . Aim of the phase 1 study is to evaluate the safety, tolerability and pharmacokinetics of oral single and multiple ascending doses of GLPG0367 . Safety and tolerability of the combination of GLPG3067 and GLPG2222 will also be evaluated. ."we plan to initiate multiple studies within our cf portfolio in the course of this year, as we get closer to our goal of initiating a patient evaluation of a triple combination therapy by mid-2017." - CSO.  Full Article

Galapagos announces two Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease
Friday, 10 Mar 2017 01:30am EST 

Galapagos Nv : announces two new phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease .studies are being led by filgotinib collaboration partner Gilead Sciences.  Full Article

Galapagos expects expenses higher than 2017 milestones - conf call
Friday, 24 Feb 2017 09:00am EST 

Galapagos NV : Expects its expenses to be a little bit higher than milestones coming in in 2017 - conf call Further company coverage: [GLPG.AS] (Gdynia Newsroom) ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;)).  Full Article

Galapagos 2016 net result turns to profit of EUR 54.0 mln
Friday, 24 Feb 2017 03:49am EST 

Galapagos NV : 2016 revenues increased by 91.0 million euros ($96.41 million) to 151.6 million euros . 2016 operating loss reduced by 77.9 million euros to 11.5 euros million . 2016 net profit of 54.0 million euros, compared to a net loss of 118.4 million euros in 2015 . 2016 cash balance increased by 632.7 million euros to 980.9 million euros at year-end . Starts three Phase 3 studies with Filgotinib .Expects an operational use of cash of 135-155 million euros during 2017.  Full Article

Galapagos increases share capital through warrant exercises
Wednesday, 30 Nov 2016 03:26am EST 

Galapagos NV : Announced on Tuesday an increase of share capital through warrant exercises . Issued 86,250 new ordinary shares on Nov. 28, 2016 for a total capital increase (including issuance premium) of 771,337.50 euros ($819,854.63) . In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15,000 warrants. . Two other Executive Committee members exercised an aggregate number of 65,000 warrants .In accordance with Belgian transparency legislation, Galapagos notes that its total share capital currently amounts to 250,187,166.48 euros, the total number of securities conferring voting rights is 46,256,078.  Full Article

Galapagos gets orphan drug designation in EU for GLPG1690 in idiopathic pulmonary fibrosis
Tuesday, 6 Sep 2016 01:30am EDT 

Galapagos NV :Orphan drug designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis.  Full Article

Galapagos to be included in AEX index
Thursday, 9 Jun 2016 01:30am EDT 

Galapagos NV : Says selected for AEX index <.AEX> .Inclusion is effective June 20, 2016.  Full Article

Galapagos creates new warrant plan
Thursday, 2 Jun 2016 02:39am EDT 

Galapagos NV : Announced on Wednesday the creation of 865,000 warrants under new warrant plans . Warrants created under Warrant Plan 2016 and Warrant Plan 2016 RMV were offered on June 1, 2016 . Warrants have an exercise term of eight years as of the date of the offer and have an exercise price of 46.10 euros ($51.65) .Warrants as such will not be listed on any stock market.  Full Article

Galapagos says completed end-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis
Tuesday, 24 May 2016 04:09pm EDT 

Galapagos Nv : Successful completion of end-of-phase 2 FDA and EMA consultations in rheumatoid arthritis (RA) . Completion of discussions with regulatory authorities in US and Europe . Discloses doses for Finch global phase 3 program with filgotinib in RA . Finch program will investigate efficacy and safety of 100 mg and 200 mg filgotinib once-daily, with dosing expected to begin in Q3'16 . Finch phase 3 program will also contain a dedicated male patient testicular safety study .Gilead expects to initiate a phase 3 study with filgotinib in Crohn's disease and a phase 2/3 study in ulcerative colitis in Q3 '16.  Full Article

Galapagos listing of existing shares on Euronext Brussels & Amsterdam
Tuesday, 17 May 2016 01:05am EDT 

Galapagos NV :6,760,701 shares subscribed to by Gilead on 19 January have been admitted to trading on Euronext Brussels and Amsterdam.  Full Article

More From Around the Web

BRIEF-Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067

* Third potentiator in growing portfolio of cystic fibrosis drug candidates